Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing awareness and acceptance about sex reassignment treatments
3.2.1.2 Rise in availability of novel hormonal therapies with better efficacy
3.2.1.3 Rising number of gender-affirming surgeries
3.2.2 Industry pitfalls & challenges
3.2.2.1 Ambiguous regulatory scenario for sex reassignment drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 LGBT scenario
3.7 Technology landscape
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Future market trends
3.11 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Gender Transition, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Male-To-Female (MTF)
5.3 Female-To-Male (FTM)
Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Estrogen
6.3 Testosterone
6.4 Puberty blockers
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacies
7.3 Retail pharmacies
7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Zone, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 East North Central
8.3 West South Central
8.4 South Atlantic
8.5 North East
8.6 East South Central
8.7 West North Central
8.8 Pacific Central
8.9 Mountain States
Chapter 9 Company Profiles
9.1 ASCEND Therapeutics US, LLC
9.2 BIOTE MEDICAL, LLC
9.3 Eli Lilly and Company
9.4 Endo International plc
9.5 Novartis AG
9.6 Noven Pharmaceuticals, Inc.
9.7 Novo Nordisk A/S
9.8 Pfizer Inc.
9.9 Teva Pharmaceutical Industries Ltd.
9.10 Viatris Inc.
